• Total FY25 revenues of $7.5 million, up 13% on the previous year
• Strong EBITDA of $1.61 million
• Increased Gross Margin to 82% (up 1%)
• Cash position of $4.2 million

Pharmx Technologies Limited (ASX: PHX) today announced strong results for the year ended 30 June 2025. Total FY25 revenues were $7.5 million, up 13% on the previous corresponding period, driven by increased account connections and transaction values across the Pharmx product suite. EBITDA was $1.6 million, representing a 13% decline on the prior year, due to significant investments in development, sales and marketing capability, and IT infrastructure. These initiatives enabled the successful launch of the Supplier and Pharmacy Portals and positioned the business for sustained future growth. Pharmx continued to generate positive underlying operating cash flows, with $4.2 million cash on hand at year end. This strong position was achieved while funding growth initiatives, finalizing the settlement of the Fred IT court case, and completing the acquisition of the Marketplace intellectual property. The company increased supplier partners by 16% and total accounts by 7%, delivering an 11% uplift in recurring revenue and positioning the business for continued growth. The value of invoices processed in FY25 increased 18% year-on-year, with new Zealand supplier revenue up 58% and network user revenue up 32%. The Marketplace saw a 114% increase in orders, a 244% increase in total processed invoice value, and a 49% increase in average order value. Pharmx advanced its key market partnerships, increasing the number of connected partners by 16%, and signed significant agreements with Toniq and Diabetes Australia, unlocking new revenue opportunities. The company launched the Supplier and Pharmacy Portals, delivered major Marketplace updates, introduced an AI-powered Analytics Platform, and completed infrastructure upgrades to enhance management, data flow, and security.

Pharmx expects to deliver continued revenue growth, with FY26 revenues forecast to exceed $8.5 million, representing a year-on-year increase of over 13%. EBITDA margins are expected to improve, reaching 22-24% in FY26, as the company realizes the benefits of its strategic investments.

Pharmx remains dedicated to making a difference in healthcare by reimagining how the industry connects. With over 18 years of service to the industry, the company is committed to delivering solutions that drive value for its customers and transform how the sector trades. Backed by a strong balance sheet, a clear strategic roadmap, a highly experienced team, and favorable market conditions, Pharmx is well-positioned to capitalize on opportunities ahead and continue its growth trajectory.